Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...
Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the ...
Since 2017, Merck (known as MSD outside of the U.S. and Canada), GSK and Eisai have been partnering to donate Mectizan, albendazole, and DEC, respectively, to accelerate the elimination of LF in ...
KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...
PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...
Global Child Forum, in partnership with Boston Consulting Group (BCG), today released its largest benchmark report to date, evaluating over 1,800 of the world's most influential companies. The report ...
Sol Chip Receives Order for 20,000 of its SolRad Energy-saving Units from European Real Estate Giant
Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of a previously announced partnership with Merck, ...
Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback